Crinecerfont

Crinecerfont
Clinical data
Other names	SSR-125543
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine;
CAS Number	752253-39-7;
PubChem CID	5282340;
UNII	MFT24BX55I;
CompTox Dashboard (EPA)	DTXSID10996687 ;
Chemical and physical data
Formula	C27H28ClFN2OS
Molar mass	483.04 g·mol−1

Crinecerfont is a corticotropin-releasing factor type 1 receptor (CRF1R) antagonist developed to treat classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD). It is hoped to reduce the need for long-term, high dose glucocorticoid therapy and its associated adverse effects in people with CAH.^[1]^[2]^[3]^[4]

References[edit]

^ Auchus, Richard J; Sarafoglou, Kyriakie; Fechner, Patricia Y; Vogiatzi, Maria G; Imel, Erik A; Davis, Shanlee M; Giri, Nagdeep; Sturgeon, Julia; Roberts, Eiry; Chan, Jean L; Farber, Robert H (17 February 2022). "Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia". The Journal of Clinical Endocrinology & Metabolism. 107 (3): 801–812. doi:10.1210/clinem/dgab749. PMC 8851935. PMID 34653252.
^ Newfield, Ron S; Sarafoglou, Kyriakie; Fechner, Patricia Y; Nokoff, Natalie J; Auchus, Richard J; Vogiatzi, Maria G; Jeha, George S; Giri, Nagdeep; Roberts, Eiry; Sturgeon, Julia; Chan, Jean L; Farber, Robert H (18 October 2023). "Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia". The Journal of Clinical Endocrinology & Metabolism. 108 (11): 2871–2878. doi:10.1210/clinem/dgad270. PMC 10583973. PMID 37216921.
^ Auchus, Richard J; Sarafoglou, Kyriakie; Fechner, Patricia Y; Vogiatzi, Maria; Giri, Nagdeep; Roberts, Eiry; Sturgeon, Julia; Farber, Robert (8 May 2020). "OR25-03 The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Results from A Multiple-Dose Phase 2 Study". Journal of the Endocrine Society. 4 (Supplement_1). doi:10.1210/jendso/bvaa046.221. PMC 7209526.
^ Auchus, Richard; Chan, Jean; Farber, Robert; Fechner, Patricia; Giri, Nagdeep; Nokoff, Natalie; Roberts, Eiry; Sarafoglou, Kyriakie; Sturgeon, Julia; Vogiatzi, Maria; Newfield, Ron (1 November 2022). "OR18-4 Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia". Journal of the Endocrine Society. 6 (Supplement_1): A618. doi:10.1210/jendso/bvac150.1281. PMC 9625506.

[1] Auchus, Richard J; Sarafoglou, Kyriakie; Fechner, Patricia Y; Vogiatzi, Maria G; Imel, Erik A; Davis, Shanlee M; Giri, Nagdeep; Sturgeon, Julia; Roberts, Eiry; Chan, Jean L; Farber, Robert H (17 February 2022). "Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia". The Journal of Clinical Endocrinology & Metabolism. 107 (3): 801–812. doi:10.1210/clinem/dgab749. PMC 8851935. PMID 34653252.

[2] Newfield, Ron S; Sarafoglou, Kyriakie; Fechner, Patricia Y; Nokoff, Natalie J; Auchus, Richard J; Vogiatzi, Maria G; Jeha, George S; Giri, Nagdeep; Roberts, Eiry; Sturgeon, Julia; Chan, Jean L; Farber, Robert H (18 October 2023). "Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia". The Journal of Clinical Endocrinology & Metabolism. 108 (11): 2871–2878. doi:10.1210/clinem/dgad270. PMC 10583973. PMID 37216921.

[3] Auchus, Richard J; Sarafoglou, Kyriakie; Fechner, Patricia Y; Vogiatzi, Maria; Giri, Nagdeep; Roberts, Eiry; Sturgeon, Julia; Farber, Robert (8 May 2020). "OR25-03 The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Results from A Multiple-Dose Phase 2 Study". Journal of the Endocrine Society. 4 (Supplement_1). doi:10.1210/jendso/bvaa046.221. PMC 7209526.

[4] Auchus, Richard; Chan, Jean; Farber, Robert; Fechner, Patricia; Giri, Nagdeep; Nokoff, Natalie; Roberts, Eiry; Sarafoglou, Kyriakie; Sturgeon, Julia; Vogiatzi, Maria; Newfield, Ron (1 November 2022). "OR18-4 Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia". Journal of the Endocrine Society. 6 (Supplement_1): A618. doi:10.1210/jendso/bvac150.1281. PMC 9625506.

[1]

[2]

[3]

[4]